Measure utilization with episodes of care
Symmetry® Episode Treatment Groups® (ETG®) captures the relevant services — including prescriptions — given during the course of an individual’s treatment. It also organizes the data into meaningful episodes of care, providing the basis for valid comparisons.
Assess the cost of cancer care
Symmetry® Episode Treatment Groups® (ETG®) Oncology is a cost measurement tool. It incorporates clinical data, claims-based markers and utilization-based markers to categorize oncology episodes based on medically necessary total episode cost. This allows for a fair and more accurate comparison of costs between health groups and providers.
Evaluate clinical specialty performance
Symmetry® Procedure Episode Groups® (PEG®) is the industry-first foundation for enhanced analysis by procedure. PEG identifies complete procedure episodes for better understanding of the cost and quality of surgical procedures, work-ups and post-procedural services.
Predict future health care utilization
Symmetry® Episode Risk Groups® (ERG®) helps you accurately assess current health care risk and predict future health care risk for individuals and groups. This boosts the effectiveness of network and care management programs. It also enhances the efficiency of underwriting.
Assess quality of care compared to national standards
Symmetry® EBM Connect® is a quality-measurement tool. It helps increase compliance with evidence-based care standards to enhance care quality and improve outcomes. Standards are sourced from national standards specifications from organizations such as HEDIS, MIPS, AHRQ and PQA.
Measure standards of care in oncology
Symmetry® EBM Connect® Oncology is a quality-measurement tool specific to cancer care. It facilitates increased compliance with evidence-based care standards to improve care quality and drive better treatment outcomes.
Analyze future risk and health care usage
Symmetry® Risk Engine (SRE) helps health plans accurately identify and assess future risk to predict potential medical and pharmaceutical costs.